Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Selective histone deacetylase small molecule inhibitors: recent progress and perspectives
Haitao Qin, Huan‐Qiu Li, Feng Liu
Expert Opinion on Therapeutic Patents (2016) Vol. 27, Iss. 5, pp. 621-636
Closed Access | Times Cited: 88

Showing 1-25 of 88 citing articles:

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1164
p53 modifications: exquisite decorations of the powerful guardian
Yanqing Liu, Omid Tavana, Wei Gu
Journal of Molecular Cell Biology (2019) Vol. 11, Iss. 7, pp. 564-577
Open Access | Times Cited: 338
Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress
Маргарита Е. Неганова, С. Г. Клочков, Yulia Aleksandrova, et al.
Seminars in Cancer Biology (2020) Vol. 83, pp. 452-471
Closed Access | Times Cited: 130
Cancer combination therapies with artemisinin-type drugs
Thomas Efferth
Biochemical Pharmacology (2017) Vol. 139, pp. 56-70
Closed Access | Times Cited: 115
HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis
Xing Lyu, Min Hu, Jieting Peng, et al.
Therapeutic Advances in Chronic Disease (2019) Vol. 10
Open Access | Times Cited: 108
PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells
Linglong Yin, Youhong Liu, Yuchong Peng, et al.
Journal of Experimental & Clinical Cancer Research (2018) Vol. 37, Iss. 1
Open Access | Times Cited: 104
Multitargeting HDAC Inhibitors Containing a RAS/RAF Protein Interfering Unit
Yuanjiang Wang, Jianluo Zhang, Kun Li, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 3, pp. 2066-2082
Closed Access | Times Cited: 9
HDAC inhibitors as epigenetic regulators for cancer immunotherapy
Mariarosaria Conte, Raffaele De Palma, Lucia Altucci
The International Journal of Biochemistry & Cell Biology (2018) Vol. 98, pp. 65-74
Closed Access | Times Cited: 74
Epigenetics and Bone Remodeling
Ali Husain, Matlock A. Jeffries
Current Osteoporosis Reports (2017) Vol. 15, Iss. 5, pp. 450-458
Open Access | Times Cited: 70
Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC)
Fangyuan Cao, Sander de Weerd, Deng Chen, et al.
European Journal of Medicinal Chemistry (2020) Vol. 208, pp. 112800-112800
Open Access | Times Cited: 64
Targeting epithelial–mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring
Sugandha Bhatia, James Monkman, Alan Kie Leong Toh, et al.
Biochemical Journal (2017) Vol. 474, Iss. 19, pp. 3269-3306
Closed Access | Times Cited: 63
Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors
Giuseppe Campiani, Caterina Cavella, J.D. Osko, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 14, pp. 9960-9988
Open Access | Times Cited: 45
Epigenetics as a versatile regulator of fibrosis
Yang Liu, Dongsheng Wen, Chiakang Ho, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 22
Discovery of novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors for the efficient treatment of idiopathic pulmonary fibrosis (IPF) in vitro and in vivo
Yanchun Li, Huali Yang, Xiangling Zhao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116608-116608
Closed Access | Times Cited: 7
Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer
Lin‐Lin Cao, Xiaoxu Song, Lin Pei, et al.
Medicine (2017) Vol. 96, Iss. 31, pp. e7663-e7663
Open Access | Times Cited: 60
The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
Fangyuan Cao, Martijn R. H. Zwinderman, Frank J. Dekker
Molecules (2018) Vol. 23, Iss. 3, pp. 551-551
Open Access | Times Cited: 57
Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines
Kalpana Tilekar, Neha Upadhyay, Niklas Jänsch, et al.
Bioorganic Chemistry (2019) Vol. 95, pp. 103522-103522
Closed Access | Times Cited: 43
Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation
Neha Upadhyay, Kalpana Tilekar, Niklas Jänsch, et al.
Bioorganic Chemistry (2020) Vol. 100, pp. 103934-103934
Open Access | Times Cited: 43
Role of SIRT1 and Progesterone Resistance in Normal and Abnormal Endometrium
Tae Hoon Kim, Steven L. Young, Tsutomu Sasaki, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 3, pp. 788-800
Open Access | Times Cited: 36
HDAC Inhibitory and Anti-Cancer Activities of Curcumin and Curcumin Derivative CU17 against Human Lung Cancer A549 Cells
Narissara Namwan, Gulsiri Senawong, Chanokbhorn Phaosiri, et al.
Molecules (2022) Vol. 27, Iss. 13, pp. 4014-4014
Open Access | Times Cited: 26
Investigating Potential Cancer Therapeutics: Insight into Histone Deacetylases (HDACs) Inhibitions
Basharat Ahmad, Aamir Saeed, Ahmed Al-Amery, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 444-444
Open Access | Times Cited: 5
Narrower insight to SIRT1 role in cancer: A potential therapeutic target to control epithelial–mesenchymal transition in cancer cells
Jalal Choupani, Sima Mansoori Derakhshan, Sahar Bayat, et al.
Journal of Cellular Physiology (2017) Vol. 233, Iss. 6, pp. 4443-4457
Closed Access | Times Cited: 48
Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation
Barbara Vergani, Giovanni Sandrone, Mattia Marchini, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 23, pp. 10711-10739
Closed Access | Times Cited: 42
β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma
Yong Ling, Weijie Gao, Chang‐Chun Ling, et al.
European Journal of Medicinal Chemistry (2019) Vol. 168, pp. 515-526
Closed Access | Times Cited: 39
Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways
Yong Ling, Yangyang Li, Rui Zhu, et al.
Journal of Natural Products (2019) Vol. 82, Iss. 6, pp. 1442-1450
Closed Access | Times Cited: 32
Page 1 - Next Page

Scroll to top